OPCH

Option Care Health, Inc.

No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.

Days to cover (short int.)

4.7d↓-3.4%

as of 2026-07-31

News Summary

Negative

Option Care Health beat Q2 2026 expectations with adjusted EBITDA of $117.5m and raised full-year revenue guidance, but the stock remains down 26% YTD driven by Stelara patent loss and chronic therapy headwinds. While acute therapies show sequential improvement and chronic therapies have stabilized, execution credibility concerns have prompted analyst downgrades and persistent valuation pressure despite recent 90-day recovery.

Red flags

•Stelara patent loss driving 40% share decline since January 2026 with ongoing insurance coverage switches impacting revenue and gross profit
•Chronic therapies remain a pressure point despite stabilization; CID patient retention issues drove Q1 guidance cut
•Stock down 26% YTD and 15.6% over 1-year despite Q2 beat, indicating persistent investor skepticism on execution
•Two analyst downgrades in 2026 (Stephens to Equal Weight, BofA to Neutral) citing execution concerns and revenue outlook doubts
•Stock fell 6.1% immediately after Q2 beat despite EPS and EBITDA ahead of expectations, signaling lack of confidence in underlying trends

Fund 13D/13G Filings (1)

Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).

Fund	Form	∆ Shares	% of Class	Since Filing	Filed	Src
Durable Capital Partners	SC 13G/A	—	3.9%	-0.1% vs SPY -1.9% abs	2026-08-14	↗